Effect of irreversibly glycated LDL in human vascular smooth muscle cells: Lipid loading, oxidative and inflammatory stress

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 12, 2010, Pages 2790-2802

  Sima, Anca V ^a   Botez, Gabriela M ^a   Stancu, Camelia S ^a   Manea, Adrian ^a   Raicu, Monica ^a   Simionescu, Maya ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

AGE LDL; CD36; Glycated LDL; Lipid loading; LRP1; MCP 1; NADPH oxidase; RAGE; SMC proliferation; Vascular hSMC

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CD36 ANTIGEN; CYBA PROTEIN, HUMAN; GLYCOSYLATED LIPOPROTEINS, LDL; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP1 PROTEIN, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL CYTOSOL FACTOR 67K; NOX1 PROTEIN, HUMAN; NOX4 PROTEIN, HUMAN; PHOSPHOPROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ARTERY; ARTICLE; ATHEROSCLEROSIS; BLOOD; CELL CULTURE; CHEMISTRY; CYTOLOGY; DIABETES MELLITUS; ENDOTHELIUM CELL; GENE EXPRESSION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; VASCULAR SMOOTH MUSCLE;

ANTIGENS, CD; ANTIGENS, CD36; ARTERIES; ATHEROSCLEROSIS; CELLS, CULTURED; CHEMOKINE CCL2; DIABETES COMPLICATIONS; ENDOTHELIAL CELLS; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; LDL-RECEPTOR RELATED PROTEIN 1; LIPOPROTEINS, LDL; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHOPROTEINS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC;

EID: 78650064089     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00933.x     Document Type: Article

References (48)

1. Simionescu M, Popov D, Sima A, et al. Pathobiochemistry of combined diabetes and atherosclerosis studied on a novel animal model. The hyperlipemic-hyperglycemic hamster. Am J Pathol. 1996; 148: 997-1014.
2. Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med. 2006; 147: 211-9.
3. Shiu SW, Tan KC, Wong Y, et al. Glycoxidized LDL increases lectin-like oxidized low density lipoprotein receptor-1 in diabetes mellitus. Atherosclerosis. 2009; 203: 522-7.
4. Younis N, Sharma R, Soran H, et al. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol. 2008; 19: 378-84.
5. Stitt AW, He C, Friedman S, et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med. 1997; 3: 617-27.
6. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008; 28: 812-9.
7. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 1994; 91: 9441-5.
8. Sima A, Stancu C. Modified lipoproteins accumulate in human coronary atheroma. J Cell Mol Med. 2002; 6: 110-1.
9. Sima A, Popov D, Starodub O, et al . Pathobiology of the heart in experimental diabetes: immunolocalization of lipoproteins, immunoglobulin G, and advanced glycation endproducts proteins in diabetic and/or hyperlipidemic hamster. Lab Invest. 1997; 77: 3-18.
10. Petry A, Djordjevic T, Weitnauer M, et al. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal. 2006; 8: 1473-84.
11. Soro-Paavonen A, Watson AM, Li J, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008; 57: 2461-9.
12. Yin CC, Huang KT. H2O2 but not O2- elevated by oxidized LDL enhances human aortic smooth muscle cell proliferation. J Biomed Sci. 2007; 14: 245-54.
13. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002; 8: 1235-42.
14. Dragomir E, Manduteanu I, Calin M, et al. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb Haemost. 2008; 100: 1155-65.
15. Nistor A, Simionescu M. Uptake of low density lipoproteins by the hamster lung. Interactions with capillary endothelium. Am Rev Respir Dis. 1986; 134: 1266-72.
16. Nivoit P, Wiernsperger N, Moulin P, et al. Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients. Diabetologia. 2003; 46: 1550-8.
17. Murtiashaw MH, Young JE, Strickland AL, et al. Measurement of nonenzymatically glucosylated serum protein by an improved thiobarbituric acid assay. Clin Chim Acta. 1983; 130: 177-87.
18. Markwell MA, Haas SM, Bieber LL, et al. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978; 87: 206-10.
19. Krishnamurti U, Rondeau E, Sraer JD, et al. Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem. 1997; 272: 27966-70.
20. Fogelman AM, Shechter I, Seager J, et al. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA. 1980; 77: 2214-8.
21. Tirziu D, Jinga VV, Serban G, et al. The effects of low density lipoproteins modified by incubation with chondroitin 6-sulfate on human aortic smooth muscle cells. Atherosclerosis. 1999; 147: 155-66.
22. Gamble W, Vaughan M, Kruth HS, et al. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res. 1978; 19: 1068-70.
23. Rago R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem. 1990; 191: 31-4.
24. Ungvari Z, Csiszar A, Edwards JG, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2003; 23: 418-24.
25. Skatchkov MP, Sperling D, Hink U, et al. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun. 1999; 254: 319-24.
26. Li JM, Mullen AM, Yun S, et al. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res. 2002; 90: 143-50.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-8.
28. Tames FJ, Mackness MI, Arrol S, et al. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis. 1992; 93: 237-44.
29. Akanji AO, Abdella N, Mojiminiyi OA. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta. 2002; 317: 171-6.
30. Cohen MP, Jin Y, Lautenslager GT. Increased plasma glycated low-density lipoprotein concentrations in diabetes: a marker of atherogenic risk. Diabetes Technol Ther. 2004; 6: 348-56.
31. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003; 285: R277-97.
32. Zhang L, Sheppard OR, Shah AM, et al. Positive regulation of the NADPH oxidase NOX4 promoter in vascular smooth muscle cells by E2F. Free Radic Biol Med. 2008; 45: 679-85.
33. Azumi H, Inoue N, Takeshita S, et al. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation. 1999; 100: 1494-8.
34. Manea A, Manea SA, Gafencu AV, et al. Regulation of NADPH oxidase subunit p22(phox) by NF-κB in human aortic smooth muscle cells. Arch Physiol Biochem. 2007; 113: 163-72.
35. Manea A, Manea SA, Gafencu AV, et al. AP-1-dependent transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: role of p22phox subunit. Arterioscler Thromb Vasc Biol. 2008; 28: 878-85.
36. Gauss KA, Nelson-Overton LK, Siemsen DW, et al. Role of NF-κappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha. J Leukoc Biol. 2007; 82: 729-41.
37. Gauss KA, Bunger PL, Quinn MT. AP-1 is essential for p67(phox) promoter activity. J Leukoc Biol. 2002; 71: 163-72.
38. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, et al. Cholesteryl esters of aggregated LDL are internalized by selective uptake in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2006; 26: 117-23.
39. Moro E, Alessandrini P, Zambon C, et al. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition Diabet Med. 1999; 16: 663-9.
40. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes. 1992; 41: 67-73.
41. Ohgami N, Nagai R, Ikemoto M, et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem. 2001; 276: 3195-202.
42. De Oliveira Silva C, Delbosc S, Arais C, et al. Modulation of CD36 protein expression by AGEs and insulin in aortic VSMCs from diabetic and non-diabetic rats. Nutr Metab Cardiovasc Dis. 2008; 18: 23-30.
43. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993; 143: 1699-712.
44. Isoda K, Folco E, Marwali MR, et al. Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis. Atherosclerosis. 2008; 198: 307-12.
45. Sukhanov S, Higashi Y, Shai SY, et al. Novel effect of oxidized low-density lipoprotein: cellular ATP depletion via downregulation of glyceraldehyde-3-phosphate dehydrogenase. Circ Res. 2006; 99: 191-200.
46. Ballinger ML, Thomas MC, Nigro J, et al. Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. Kidney Int. 2005; 68: 2756-65.
47. Cho HM, Choi SH, Hwang KC, et al. The Src/PLC/PKC/MEK/ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by glycated LDL. Mol Cells. 2005; 19: 60-6.
48. Wu S, Song T, Zhou S, et al. Involvement of Na+/H+ exchanger 1 in advanced glycation end products-induced proliferation of vascular smooth muscle cell. Biochem Biophys Res Commun. 2008; 375: 384-9.